SCHEMBL1324255

SCHEMBL1324255

NNC1(C(=O)O)CC(=O)NC1=O

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CYP19A1 P11511 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1325877 0.68 CYP19A1 (0.36) TSHRNPSR1CYP19A1
SCHEMBL1322984 0.68 CYP19A1 (0.36) TSHRNPSR1CYP19A1
SCHEMBL4356813 0.68 CYP19A1 (0.36) TSHRNPSR1CYP19A1
Bicarbonate SCHEMBL9560500 0.63 TSHR (0.37) TSHRNPSR1CYP19A1
SCHEMBL5163675 0.62 DDB1 (0.31)
Oxalic Acid SCHEMBL9221357 0.61 TSHR (0.35) TSHRNPSR1
SCHEMBL15636565 0.60 TSHR (0.31) TSHRNPSR1
SCHEMBL12385121 0.60 TSHR (0.48) TSHRNPSR1CYP19A1
Acetic Acid SCHEMBL3681508 0.60 TSHR (0.43) TSHRNPSR1CYP19A1
SCHEMBL4637001 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003808-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-23 US claimed
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME TANAKA DAISUKE 2011-08-18 US claimed
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-10-08 US claimed
US-8415487-B2 Process for preparing (3R)-2′-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-A]pyrazine]-1′,2,3′,5(2H′)-tetraone DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-04-09 US disclosed
US-8389742-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-8389742-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-8389742-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-03-05 US disclosed
US-20120010405-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND TANAKA DAISUKE (JP) 2012-01-12 US disclosed
US-8058456-B2 Optically active 3-amino-2,5-dioxopyrrolidine-3-carboxylate, process for production of the compound, and use of the compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-11-15 US disclosed
US-8003808-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-23 US disclosed
US-8003808-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-23 US disclosed
US-8003808-B2 3-hydrazino-2,5-dioxopyrrolidine-3-carboxylates, process for production of the same, and use of the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-08-23 US disclosed
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME TANAKA DAISUKE 2011-08-18 US disclosed
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME TANAKA DAISUKE 2011-08-18 US disclosed
US-20090286980-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-11-19 US disclosed
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-10-08 US disclosed
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2009-10-08 US disclosed
WO-2008004415-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253917-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATES, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME SLC5A1, TERT, CBR3 TSHR 570/4885NPSR1 2349/4885CYP19A1 3751/4885
US-20090286980-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND REN, GPR119, RANBP1 TSHR 2500/4885NPSR1 1374/4885CYP19A1 2942/4885
US-20120010405-A1 OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND REN, GPR119, RANBP1 TSHR 2500/4885NPSR1 1374/4885CYP19A1 2942/4885
US-20110201807-A1 3-HYDRAZINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE SAME, AND USE OF THE SAME CBR3, TERT, NOX4 TSHR 511/4885NPSR1 1966/4885CYP19A1 3717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.